Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Infections

Rare Diseases

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Mycoses

Mycosis Fungoides

Lymphoma, T-Cell, Cutaneous

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Peripheral T-cell Lymphoma

Cutaneous T-cell Lymphoma

Forodesine 200 mg

Nashat Gabrail, MD

Madeleine Duvic, MD

Youn Kim, MD

Andres Forero-Torres, M.D.

Alan B Fleischer, Jr., MD

Gary S. Wood, MD

Andre Goy, MD

Larisa Geskin, MD

Nancy Bartlett, MD

Francine Foss, MD

Miles Prince, MD

Elise Olsen, MD

Sareeta S Parker, MD

Neil J Korman, MD, PhD

Francesco Turturro, MD

Andrei R Shustov, MD

This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) \[complete response (CR) or partial response (PR)\] in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB, III, or IVA treated with oral forodesine.

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma

BioCryst Pharmaceuticals

Symptoms and General Pathology

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Hematologic Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Forodesine

To determine the dose and duration of treatment for the best overall response with Forodesine in relapsed B-cell chronic lymphocytic leukemia

An open label, multi centre, three arm, dose finding Phase 1 trial with Forodesine as a single drug treatment in patients with relapsed CLL to establish dose and duration of treatment resulting in the best achievable response with Forodesine as a single drug treatment.

Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

Phase 1, Multicentre, Open-label, Dose Finding Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

Mundipharma Research Limited

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma	NCT00501735	Cutaneous T-cel...	Forodesine 200 ...	18 Years -	BioCryst Pharmaceuticals
Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia	NCT00646165	B-cell Chronic ...	Forodesine	18 Years -	Mundipharma Research Limited
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma	NCT00501735	Cutaneous T-cel...	Forodesine 200 ...	18 Years -	BioCryst Pharmaceuticals

Spots Global Cancer Trial Database for forodesine

Every month we try and update this database with for forodesine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for forodesine

Every month we try and update this database with for forodesine cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for forodesine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.